rel
recent
discov
nucleic
acid
particip
varieti
biolog
function
besid
storag
transmiss
genet
inform
quit
apart
nucleotid
sequenc
clear
structur
nucleic
acid
play
essenti
role
function
enabl
catalysi
specif
bind
reaction
vitro
select
evolut
strategi
extrem
use
analysi
function
rna
dna
molecul
help
expand
knowledg
function
repertoir
identifi
optim
dna
rna
molecul
potenti
therapeut
diagnost
applic
great
progress
made
field
prompt
develop
ex
vivo
method
select
function
nucleic
acid
cellular
environ
review
summar
import
recent
applic
vitro
ex
vivo
select
strategi
aim
explor
therapeut
potenti
nucleic
acid
nucleic
acid
particularli
rna
extrem
versatil
molecul
apart
role
carrier
genet
inform
also
express
phenotyp
eg
may
show
catalyt
activ
specif
bind
function
capac
recruit
specif
molecul
appear
sequenc
variat
nucleic
acid
case
provid
advantag
organ
key
featur
natur
evolut
last
year
advanc
molecular
biolog
biotechnolog
seen
develop
method
allow
effect
natur
aris
variat
mimick
laboratori
spiegelman
group
first
observ
evolut
vitro
author
report
chang
rna
genom
bacteriophag
replic
led
format
rna
molecul
effici
copi
viral
replicas
genom
lack
unnecessari
sequenc
synthes
greater
rate
howev
find
fell
oblivion
great
potenti
vitro
select
evolut
techniqu
report
three
independ
group
sinc
numer
author
use
technolog
studi
chemic
catalyt
properti
nucleic
acid
inform
see
also
help
uphold
rna
world
hypothesi
seem
like
may
soon
applic
biomedicin
inde
new
select
method
known
ex
vivo
select
procedur
use
identifi
molecul
target
virus
subcellular
fraction
even
whole
cell
techniqu
overcom
limit
impos
vitro
technolog
provid
new
environ
condit
explor
properti
function
nucleic
acid
review
highlight
recent
advanc
vitro
ex
vivo
select
procedur
nucleic
acid
discuss
potenti
applic
biomedicin
vitro
select
strategi
use
select
nucleic
acid
larg
varieti
properti
although
strategi
differ
accord
featur
phenotyp
sought
vitro
select
method
follow
threestep
pattern
figur
genet
variabl
introduc
system
gener
chemic
synthesi
yield
nucleic
acid
popul
heterogen
determin
fix
number
nucleotid
mutagen
mutat
rate
per
nucleotid
case
complet
random
synthesi
involv
fix
number
nucleotid
yield
start
popul
variant
molecul
priori
differ
sequenc
structur
variabl
region
constant
sequenc
primer
bind
site
pb
flank
variabl
region
incorpor
design
start
popul
facilit
amplif
desir
molecul
although
limit
structur
divers
rna
popul
specif
conform
differ
approach
tri
minim
effect
pbss
eg
addit
custom
primer
adapt
ligat
amplif
remov
prior
select
step
select
strategi
need
specif
design
accord
phenotyp
sought
initi
pool
variant
usual
contain
activ
molecul
correspond
desir
phenotyp
enrich
made
possibl
properli
design
select
step
select
inact
molecul
may
also
import
sinc
analysi
molecul
provid
valuabl
inform
sequenc
structur
requir
activ
molecul
vitro
select
strategi
wide
use
select
nucleic
acid
capabl
catalyz
specif
chemic
reaction
ie
dnazym
ribozym
strategi
also
success
use
identifi
dna
rna
molecul
affin
specif
ligand
ie
aptam
known
selex
stand
systemat
evolut
ligand
exponenti
enrich
sequenc
variant
separ
activ
satisfi
select
criteria
inact
molecul
activ
molecul
select
amplifi
pcr
result
product
new
pool
molecul
input
new
select
cycl
addit
revers
transcript
vitro
transcript
step
requir
pcr
respect
select
perform
rna
molecul
altern
activ
inact
result
pool
clone
analyz
variant
show
requir
phenotyp
need
replic
ensur
passag
next
gener
therefor
persist
popul
specif
primer
bind
site
use
amplifi
select
molecul
necessari
rna
polymeras
promot
incorpor
end
pb
amplif
step
addit
gener
step
amplifi
molecul
may
requir
addit
manipul
prior
introduct
next
round
select
select
molecul
ssdna
dna
strand
must
separ
posit
one
isol
eg
incorpor
biotinyl
residu
unwant
strand
via
asymmetr
pcr
result
describ
select
cycl
popul
enrich
soughtaft
molecul
compos
entir
produc
new
select
cycl
undertaken
iter
execut
process
select
amplif
complex
origin
popul
reduc
enrich
candid
interest
process
stringenc
select
increas
achiev
isol
molecul
desir
phenotyp
great
advanc
made
vitro
select
procedur
recent
decad
help
us
improv
knowledg
plastic
nucleic
acid
potenti
applic
therapeut
tool
inde
advanc
select
strategi
within
live
cell
contempl
new
methodolog
name
accord
specif
procedur
employ
method
eg
ex
vivo
vivo
cell
select
cellselex
etc
refer
ex
vivo
select
strategi
ex
vivo
select
methodolog
follow
gener
pattern
describ
vitro
techniqu
system
mainli
use
isol
dna
rna
molecul
interfer
activ
target
molecul
express
oligonucleotid
lead
desir
cell
phenotyp
allow
select
cell
subsequ
isol
oligonucleotid
follow
principl
strategi
use
identifi
transcript
activ
regul
tmr
tetramethylrosamin
purpos
chimera
construct
tether
tmr
aptam
transcript
activ
protein
also
known
variabl
introduc
random
seven
nucleotid
within
linker
region
two
rna
domain
select
perform
yeast
cell
contain
construct
code
lacz
gene
control
lexa
oper
express
coat
protein
fusion
hybrid
protein
bind
oper
rna
hairpin
present
rna
construct
cell
express
activ
transcript
activ
capabl
growth
absenc
histidin
one
capabl
express
stringenc
select
process
increas
presenc
vari
amount
competit
inhibitor
activ
analysi
select
yeast
clone
reveal
specif
rna
sequenc
respond
tmr
enhanc
transcript
activ
effect
select
artifici
ribosom
switch
via
extern
addit
small
molecul
growth
medium
deserv
special
mention
escherichia
coli
ribosom
rna
fuse
aptazym
ribozym
capabl
bind
thiamin
pyrophosph
ttp
aptam
domain
bind
ttp
activ
ribozym
reduc
gene
express
cleav
ribosom
rna
thu
work
riboswitch
allow
identif
select
specif
e
coli
coloni
accord
phenotyp
express
ttp
riboswitch
also
includ
utr
region
report
gene
nt
upstream
shinedalgarno
sequenc
linker
element
random
e
coli
coloni
select
depend
express
report
gene
respons
ttp
ex
vivo
select
method
cell
limit
number
sequenc
studi
number
determin
number
avail
cell
anoth
problem
possibl
one
sequenc
variant
per
cell
could
lead
mani
fals
posit
ellington
group
develop
interest
strategi
allow
direct
select
activ
molecul
instead
select
cell
clone
cleavag
product
autocatalyt
ribozym
synthes
cell
nucleu
extract
via
hybrid
biotinyl
oligonucleotid
allow
direct
identif
activ
molecul
select
nucleic
acid
whole
cell
target
success
use
select
nucleic
acid
target
cell
surfac
receptor
technolog
also
known
cellselex
could
role
play
treatment
cancer
type
cancer
cell
shortag
highli
specif
surfac
marker
use
diagnost
therapeut
intent
aptam
gener
whole
live
cell
optim
molecular
probe
character
target
cell
molecular
level
bound
membran
receptor
cell
line
provid
effect
mean
identifi
diseas
marker
pharmacokinet
pharmacodynam
properti
nucleic
acid
resist
nucleas
condit
effect
therapeut
molecul
select
effect
molecul
modifi
improv
nucleas
resist
well
affin
target
cellular
uptak
select
great
divers
postselect
modif
describ
interest
therapeut
purpos
discuss
includ
modif
oligonucleotid
size
sequenc
mainli
certain
chemic
modif
review
see
advanc
chemic
synthesi
allow
product
conjug
combin
oligonucleotid
sequenc
compound
fluorophor
peptid
carbohydr
lipid
figur
modifi
oligonucleotid
show
advantag
properti
respect
nativ
form
ligand
usual
link
termini
access
region
chemic
conjug
reaction
addit
disrupt
nucleic
acid
fold
function
properti
minim
conjug
posit
ribos
involv
internucleotid
phosphodiest
bond
also
possibl
fluorophor
conjug
alreadi
use
clinic
diagnosi
eg
fluoresc
situ
hybrid
fish
molecular
beacon
fish
detect
specif
gene
cell
molecular
beacon
act
like
switch
emit
fluoresc
light
bound
target
sequenc
cell
uptak
improv
conjug
oligonucleotid
peptid
capabl
transloc
across
cell
membran
nonreceptormedi
endocytot
mechan
frequent
use
peptid
residu
third
helix
antennapedia
homeodomain
penetratin
highli
argininelysin
rich
region
tat
protein
hydrophob
signal
peptid
nuclear
local
sequenc
nl
transportan
besid
improv
cellular
uptak
peptideoligonucleotid
conjug
show
increas
stabil
nucleas
degrad
enhanc
bind
carbohydrateoligonucleotid
conjug
coc
similar
applic
addit
confer
cell
tissu
specif
bind
sugar
receptor
ie
lectin
present
cell
surfac
capabl
recogn
intern
endocytosi
glycoprotein
bear
specif
carbohydr
moieti
lipophil
oligonucleotid
conjug
loc
cholesterol
reduc
hydrophob
charact
oligonucleotid
bind
blood
lipoprotein
carrier
lipophil
oligonucleotid
also
use
design
supramolecular
assemblag
micel
vesicl
liposom
network
abil
certain
rna
polymeras
incorpor
modifi
nucleotid
grow
chain
ribonucleosid
make
possibl
use
select
procedur
popul
chemic
modifi
oligonucleotid
chemic
modif
hydroxyl
group
rna
fluoro
amino
methoxi
amido
modif
noteworthi
potenti
therapeut
applic
sinc
increas
rna
stabil
confer
greater
resist
nucleas
anoth
import
modif
therapeut
purpos
use
lock
nucleotid
lna
nucleotid
chain
lna
contain
methylen
link
ribos
ring
lock
sugar
moieti
endo
conform
gener
stabl
hybrid
ever
character
per
lna
residu
upon
bind
dna
rna
respect
thu
confer
nucleas
resist
introduct
lna
modif
vitro
select
techniqu
far
restrict
post
select
incorpor
review
see
nevertheless
recent
shown
lock
nucleotid
incorpor
enzymat
dna
rna
spiegelm
spiegel
mirror
german
unnatur
biostabl
lform
daptam
develop
allow
oligonucleotid
escap
nucleas
attack
natur
occur
protein
lchiral
therefor
natur
nucleas
digest
doligonucleotid
lnucleosid
escap
fate
obtain
spiegelm
natur
oligonucleotid
use
select
cycl
unnatur
dprotein
mirror
natur
structur
ltarget
select
process
yield
lform
aptam
sequenc
virtu
law
symmetri
recogn
natur
target
spiegelm
select
peptid
hormon
gonadotropinreleas
hormon
gnrh
ghrelin
endogen
ligand
growth
hormon
secretagogu
receptor
neutral
effect
vivo
hormon
system
administr
vitro
select
strategi
extens
success
use
character
known
ribozym
dnazym
isol
new
catalyt
nucleic
acid
unsuspect
activ
fact
first
observ
dna
molecul
catalyz
chemic
reaction
dnazym
made
use
vitro
select
strategi
although
ribozym
dnazym
extens
assay
potenti
therapeut
agent
differ
clinic
trial
alreadi
test
effici
variou
diseas
report
describ
direct
applic
vitro
select
strategi
develop
potenti
therapeut
catalyt
nucleic
acid
ellington
group
recent
describ
procedur
aim
identifi
cleav
ribozym
activ
within
cell
milieu
yet
use
therapeut
intent
work
refer
herein
describ
use
vitro
ex
vivo
select
strategi
identif
aptam
therapeut
potenti
assay
catalyt
nucleic
acid
engin
socal
ration
design
beyond
scope
review
idea
aptam
modul
activ
target
protein
emerg
basic
studi
virus
research
hiv
adenoviru
led
discoveri
virus
contain
sever
structur
rna
domain
bind
viral
cellular
protein
high
affin
specif
surprisingli
function
analys
viral
rna
ligand
demonstr
virus
evolv
aptam
either
modul
activ
protein
essenti
replic
inhibit
activ
protein
involv
cellular
antivir
respons
first
studi
perform
determin
whether
rna
aptam
could
use
inhibit
activ
pathogen
protein
publish
work
report
tar
aptam
evolv
hiv
recruit
viral
cellular
protein
viral
transcript
could
turn
viru
inhibit
replic
vitro
aptam
select
strategi
develop
prompt
idea
sulleng
group
therapeut
aptam
might
possibl
sever
aptam
complet
variou
stage
preclin
develop
number
other
current
test
clinic
tabl
inde
one
aptam
alreadi
market
therapeut
drug
sever
modif
gener
select
process
scheme
describ
order
achiev
differ
goal
exampl
toggleselex
strategi
use
select
potenti
therapeut
nucleic
acid
toggleselex
design
isol
aptam
broad
rang
specif
close
relat
target
homolog
protein
differ
speci
aptam
obtain
perform
select
procedur
relat
target
ie
homolog
protein
altern
cycl
altern
ensur
rna
dna
variant
result
select
bind
protein
like
domain
conserv
sulleng
group
describ
vitro
select
strategi
rna
aptam
bind
human
porcin
thrombin
select
toggl
protein
target
human
porcin
form
success
round
select
yield
famili
aptam
bound
thrombin
type
high
affin
characterist
member
inhibit
two
thrombin
import
function
plasma
clot
format
platelet
activ
strategi
could
facilit
isol
ligand
properti
requir
gene
therapi
therapeut
diagnost
applic
date
aptam
approv
fda
known
pegaptanib
macugen
approv
decemb
treatment
wet
type
agerel
macular
degener
amd
aptam
bind
vascular
endotheli
growth
factor
vegf
main
isoform
famili
growth
factor
involv
promot
blood
vessel
develop
mainten
via
tyrosin
kinas
receptor
signal
vegf
also
involv
sever
patholog
process
amd
diabet
retinopathi
cancer
phase
ii
clinic
trial
evalu
use
aptam
fight
diabet
retinopathi
current
underway
select
procedur
involv
modifi
rna
pool
addit
modif
made
select
ad
purin
residu
aptam
except
two
ad
cap
ad
polyethylen
glycol
peg
kd
end
figur
macugen
aptam
bind
heparinbind
domain
vegf
effici
inhibit
growth
blood
vessel
agent
particular
interest
respect
prevent
tumor
angiogenesi
differ
aptam
current
test
treatment
degen
diseas
niu
group
attempt
interfer
function
ampa
receptor
associ
cerebr
ischemia
amylotroph
later
sclerosi
select
aptam
known
act
glutam
antagonist
prevent
glutamateinduc
activ
cation
channel
interestingli
aptam
adopt
two
mutual
exclus
noninterchang
isoform
necessari
proper
inhibit
occur
recent
new
rna
aptam
isol
bind
neural
receptor
antagonist
myelinderiv
ligand
signal
block
neurit
outgrowth
bind
aptam
allow
axon
growth
rat
ganglion
cell
vitro
aptam
special
interest
search
agent
aid
neural
repair
eg
spinal
cord
trauma
aptam
also
target
diseasecaus
protein
scrapi
isoform
prion
protein
prp
sc
rna
aptam
known
shown
prevent
aggreg
cell
free
system
aptam
known
slow
aggreg
neuroblastoma
cell
aptam
target
conserv
region
involv
prion
interact
neutrophil
elastas
hne
involv
pathogenesi
inflammatori
diseas
acut
respiratori
distress
syndrom
ard
septic
shock
emphysema
arthriti
well
ischemiareperfus
injuri
coval
inhibitor
hne
diphenyl
phosphat
deriv
valin
coupl
rna
librari
enhanc
bind
hne
vitro
select
rna
aptam
conjug
dna
valp
dna
valp
isol
bind
hne
high
affin
bound
molecul
unlik
aptam
rna
dna
valp
alon
also
inhibit
lung
inflamm
ex
vivo
rat
model
ard
effici
inhibitor
hne
obtain
valyl
phosphon
dna
pool
select
aptam
inhibitor
inhibit
hne
format
two
order
magnitud
greater
dna
valp
truncat
dna
aptam
version
name
compos
two
anneal
dna
oligonucleotid
test
rat
model
lung
inflamm
found
inhibit
neutrophil
infiltr
dose
nmol
immunoglobulin
e
ige
play
import
role
protect
mammal
parasit
howev
overproduct
due
exposur
environment
antigen
result
allergi
atop
dermat
allerg
asthma
dna
select
perform
human
ige
produc
aptam
bind
high
affin
aptam
inhibit
bind
ige
receptor
also
prevent
igemedi
cellular
degranul
serum
patient
allergi
grass
pollen
patient
expos
grass
pollen
extract
dna
aptam
trigger
antiig
antibodi
reach
nm
dna
aptam
repres
novel
class
ige
inhibitor
may
prove
use
fight
allerg
diseas
cancer
one
diseas
target
aptam
alter
signal
pathway
result
escap
tumor
cell
control
cell
divis
apoptosi
format
metastas
also
promot
process
target
aptam
tyrosin
kinas
receptor
tkr
target
two
aptam
ret
rearrang
transfect
human
epiderm
growth
factor
receptor
ret
aptam
aptam
isol
ex
vivo
select
extracellular
mutant
ret
receptor
briefli
rna
popul
incub
parent
cell
line
variant
express
differ
ret
mutant
neg
select
step
unbound
fraction
rna
molecul
recov
incub
cell
express
recombin
ret
receptor
select
aptam
inhibit
neurit
outgrowth
revert
neoplast
phenotyp
cell
vitro
three
dimension
collagen
gel
matrix
cultur
aptam
aptam
known
isol
monomer
extracellular
domain
prevent
signal
via
heterodimer
cell
cultur
cell
adhes
misregul
involv
metastasi
also
prevent
aptam
plasminogen
activ
overexpress
breast
cancer
cell
bind
vitronectin
lead
loss
adhes
aptam
known
specif
plasminogen
activ
restor
cell
adhes
vitronectinco
plate
vitro
anoth
type
therapeut
signal
modul
target
nuclear
factor
insid
cell
maher
group
isol
two
rna
aptam
two
independ
vitro
select
procedur
bind
isoform
vitro
respect
aptam
underw
ex
vivo
select
use
yeast
threehybrid
system
inhibit
might
therapeut
interest
differ
type
cancer
infect
inflammatori
diseas
fact
gene
therapi
differ
aptam
administ
via
adenovir
vector
suppress
doxorubicin
resist
vivo
lung
tumor
xenograft
mous
model
inhibit
nucleophosmin
oligomer
aptam
promot
higher
level
consist
sensit
cell
dnadamagingagentinduc
apoptosi
cell
cultur
stimul
immun
system
also
use
anticanc
therapi
activ
cell
within
tumor
would
promot
cytotox
involut
respect
modul
cytotox
tcell
receptor
aptam
explor
multimer
aptam
form
frequent
improv
aptam
signal
properti
proven
especi
import
area
shown
antagonist
rna
aptam
neg
regul
tcell
activ
inhibit
function
agonist
aptam
major
costimulatori
receptor
lead
activ
cell
immun
tumor
induc
vivo
case
specif
aptam
dimer
murin
combin
dendrit
cellbas
tumor
vaccin
promot
tumor
immun
xenograft
melanoma
model
mice
aptam
also
shown
abl
promot
tumor
cell
death
express
cell
aptam
select
nucleophosmin
shown
prevent
latter
oligomer
higher
level
therefor
promot
led
apoptosi
addit
sensit
cell
dnadamag
agent
cell
cultur
increas
research
antiangiogenesi
aptam
provid
interest
result
sulleng
group
report
select
specif
rna
aptam
gene
aptam
bind
inhibit
signal
pathway
lead
reduc
surviv
huvec
cell
vitro
similarli
intraocularli
administ
aptam
bind
inhibit
angiogenesi
rat
corneal
micropocket
deoxythymidin
cap
protect
aptam
rnase
pegyl
version
molecul
shown
inhibit
tumor
angiogenesi
growth
vivo
murin
metastat
colon
cancer
model
follow
system
administr
larg
major
aptam
isol
selex
antiprolif
dna
aptam
develop
base
observ
guanosinerich
oligonucleotid
antiprolif
effect
tumor
cell
molecular
studi
shown
aptam
bind
cell
surfac
protein
nucleolin
inhibit
activ
nfkb
ubiquit
transcript
factor
intracellular
complex
format
clinic
studi
focus
patient
renal
pancreat
solid
tumor
aptam
administ
patient
continu
infus
day
selectin
famili
cell
adhes
molecul
express
leukocyt
endotheli
cell
platelet
involv
number
inflammatori
diseas
well
tissu
injuri
infect
dna
select
lselectinigg
fusion
protein
lsrg
perform
find
aptam
could
test
vivo
aptam
bound
kd
nm
truncat
version
aptam
inhibit
slrg
bind
ligand
sialyl
lewi
x
slex
ic
nm
aptam
block
lselectinmedi
adhes
human
lymphocyt
neutrophil
inhibit
human
cell
traffick
peripher
mesenter
lymph
node
scid
mice
plateletderiv
growth
factor
pdgf
ubiquit
mitogen
chemotact
growth
factor
form
three
disulphidelink
dimer
made
two
homolog
chain
b
involv
wound
heal
link
progress
numer
diseas
includ
atherosclerosi
glomerulonephr
hallmark
malign
transform
loss
depend
exogen
mitogen
stimul
mani
tumor
cell
line
thought
produc
secret
pdgf
reason
dna
select
recombin
human
pdgfab
yield
dna
specif
aptam
pdgf
bchain
bound
subnanomolar
affin
consensu
secondari
structur
motif
highaffin
ligand
threeway
helix
junction
threenucleotid
loop
branch
point
pdgf
aptam
inhibit
mitogen
effect
pdgfbb
cell
express
pdgf
receptor
pegmodifi
aptam
rat
model
mesangioprolif
glomerulonephr
led
reduct
mitos
day
day
also
reduct
prolifer
mesangi
cell
day
markedli
reduc
glomerular
express
endogen
pdgf
bchain
aptamertr
anim
also
show
reduc
influx
monocytesmacrophag
overproduct
glomerular
extracellular
matrix
day
studi
reveal
inhibit
diseas
mechan
aptam
experiment
glomerulonephr
express
pdgf
receptor
tumor
associ
increas
interstiti
fluid
pressur
ifp
dermi
reduc
gradient
capillari
interstitium
imped
exchang
solut
anticanc
agent
capillari
membran
increas
gradient
may
facilit
transport
anticanc
drug
tumor
reduc
ifp
pdgfb
aptam
test
rat
tumor
model
treat
anim
ifp
mm
hg
compar
mm
hg
scrambledrnatr
anim
anoth
dna
aptam
known
target
pdgfb
subtyp
current
undergo
phase
clinic
trial
antivascular
endotheli
growth
factor
compound
blood
fluiditi
blood
vessel
resist
involv
numer
vascular
diseas
coronari
thrombot
syndrom
myocardi
infarct
certainli
factor
must
care
control
coronari
surgeri
prolifer
cardiac
vascular
cell
key
develop
vessel
resist
diseas
cardiac
intim
hyperplasia
cardiac
hypertrophi
atherosclerosi
well
develop
malign
recent
studi
report
develop
rna
aptam
abl
specif
recogn
member
transcript
factor
involv
cell
prolifer
bind
aptam
mainli
reduc
intim
hyperplasia
patholog
prolifer
migrat
vascular
smooth
muscl
cell
vsmc
bypass
surgeri
mous
model
aptam
avoid
side
effect
deriv
cross
reactiv
member
famili
differ
approach
selex
perform
protein
find
vitro
select
rna
aptam
bind
inhibit
activ
clone
rna
found
bind
block
latter
attach
dna
bind
site
imped
activ
rna
aptam
inhibit
sphase
induct
compar
control
thu
natur
vitro
select
aptam
appear
abl
limit
cell
prolifer
coagul
signal
cascad
offer
sever
target
modul
blood
fluiditi
convers
prothrombin
thrombin
delay
long
halflif
h
aptam
target
catalyst
factor
viia
dose
depend
manner
nevertheless
rapid
restor
cascad
integr
need
prevent
harm
effect
coagul
defici
aim
rnabas
aptamerantidot
system
develop
rna
aptam
target
factor
xia
antisens
rna
molecul
design
specif
bind
aptam
antidot
bind
antidot
abolish
aptam
bind
target
therebi
revers
anticoagul
effect
figur
neither
antidot
aptam
seen
caus
advers
effect
phase
clinic
trial
ia
ib
given
healthi
peopl
patient
stabl
cardiovascular
diseas
receiv
antiplatelet
therapi
result
anoth
phase
clinic
trial
ic
indic
anticoagul
effect
modul
vari
dose
antidot
rna
recent
phase
iia
trial
percutan
coronari
inject
aptam
increas
activ
clot
time
act
patient
immedi
administr
reach
valu
close
obtain
heparin
act
valu
restor
min
administr
antidot
thrombin
natur
target
anticoagul
therapi
numer
aptam
gener
differ
capac
inhibit
activ
vitro
archemix
corp
collabor
arca
biopharma
inc
formerli
nuvelo
inc
test
dna
aptam
thrombin
phase
clinic
trial
administ
intraven
continu
infus
healthi
volunt
result
show
increas
activ
clot
time
return
baselin
administr
ceas
see
archemix
corp
websit
phase
ii
clinic
studi
current
underway
goal
use
coronari
arteri
bypass
graft
surgeri
percutan
coronari
intervent
figur
mechan
apatamerantidot
pair
anticoagul
therapyth
intrins
pathway
blood
coagul
cascad
involv
activ
factor
x
anticoagul
system
consist
drug
inject
rna
aptam
specif
bind
activ
factor
ix
ixa
prevent
proteolyt
cleavag
factor
x
antidot
rna
antisens
oligonucleotid
neutral
anticoagul
effect
aptam
presenc
antidot
aptam
releas
factor
ixa
clot
paramet
return
normal
togeth
activ
factor
viii
viiia
factor
ixa
catalyz
cleavag
factor
x
proenzym
yield
activ
factor
x
xa
requir
blood
clot
cascad
dnarna
aptam
conjug
peg
known
gener
vwf
von
willebrand
factor
central
factor
adhes
platelet
endotheli
surfac
vascular
injuri
site
examin
phase
trial
healthi
volunt
aptam
increas
platelet
function
wholeblood
assay
sensit
vwfmediat
platelet
inhibit
moreov
slow
intraven
bolu
follow
h
continu
infus
inhibit
vwf
function
return
baselin
h
administr
suspend
involv
inflamm
respons
modul
synthesi
chemokin
interferon
major
histocompat
complex
mhc
protein
growth
factor
cell
adhes
molecul
play
role
ischemiareperfus
injuri
seen
myocardi
infarct
natur
doubl
strand
dna
aptam
found
bind
high
affin
rat
cardiac
ischemiareperfus
model
aptam
significantli
reduc
expect
injuri
rat
cardiopleg
arrest
model
anim
transfect
dna
aptam
show
improv
recoveri
left
ventricular
function
well
coronari
flow
three
day
posttransfect
compar
scrambleddna
control
vs
aptamertr
group
also
show
lower
percentag
neutrophil
adhes
endotheli
cell
vs
lower
level
interleukin
vs
ngmg
aptam
also
studi
murin
model
nephriti
abolish
glomerular
inflamm
express
inflammatori
marker
intracellular
adhes
molecul
vascular
cell
adhes
molecul
rat
global
brain
ischemia
model
show
inhibit
express
aptamertr
anim
h
ischemia
moreov
day
ischemia
neuron
damag
significantli
attenu
group
compar
control
protein
differ
pathogen
also
attract
attent
research
target
inhibitori
nucleic
acid
recent
studi
report
use
aptam
extracellular
domain
erythrocyt
membran
protein
parasit
protozoan
plasmodium
falciparum
achiev
effici
inhibit
erythrocyt
rosset
blood
cultur
rna
virus
especi
hcv
main
target
therapeut
nucleic
acid
catalyt
activ
rossi
group
design
interest
ex
vivo
select
procedur
identifi
antihiv
hammerhead
ribozym
pool
hammerhead
catalyt
domain
contain
random
bind
arm
sequenc
assay
chimera
contain
thymidin
kinas
gene
cell
transfect
ribozym
popul
express
control
promot
gancyclovirresist
cell
select
antibiot
resist
suggest
presenc
activ
antihiv
ribozym
banerjea
group
design
strategi
identifi
access
cleavag
site
within
gag
rna
pick
dnazym
effect
target
two
dnazym
variant
popul
synthes
specif
first
limit
possibl
aug
target
rna
wherea
second
popul
design
cleav
potenti
target
site
option
made
possibl
either
fix
nucleotid
immedi
preced
catalyt
motif
ca
aug
cleavag
total
random
seven
base
either
side
catalyt
motif
dnazym
select
popul
show
targetspecif
cleavag
activ
presenc
mg
significantli
interf
gene
express
strategi
could
use
select
effect
target
site
target
rna
viral
protein
favorit
target
develop
therapeut
aptam
rna
aptam
select
differ
viral
enzym
protein
involv
hostcel
interact
revers
transcriptas
rt
glycoprotein
hcv
rnadepend
rna
polymeras
rdrp
sar
coronaviru
ntpasehelicas
hemagglutinin
protein
human
influenza
viru
b
show
effici
viral
inhibit
human
influenza
b
viru
hemagglutinin
protein
inhibit
vitro
rna
pool
result
round
vitro
select
studi
requir
identif
independ
aptam
recent
dna
aptam
term
describ
adopt
novel
type
dimer
quadruplex
fold
show
integras
activ
nanomolar
rang
vitro
block
sever
catalyt
amino
acid
residu
essenti
integras
function
sever
grich
dna
aptam
identifi
remark
inhibitor
valu
nanomolar
rang
one
aptam
well
studi
recent
year
astiergi
group
describ
character
two
dna
aptam
specif
bind
hepat
c
viru
hcv
rna
polymeras
inhibit
activ
vitro
aptam
compet
rna
templat
bind
enzym
block
initi
elong
phase
rna
synthesi
wherea
aptam
exclus
inhibit
initi
event
author
also
determin
addit
vitro
inhibitori
effect
rna
synthesi
aptam
interf
multipl
hcv
cell
effici
cellular
entri
short
dna
inhibitori
effect
observ
human
cell
infect
hcv
indic
aptam
use
tool
studi
hcv
rna
synthesi
therapeut
hcv
infect
also
attract
altern
innov
potenti
therapeut
approach
attract
much
hope
target
structur
domain
viral
genom
frequent
concentr
within
untransl
termin
region
utr
transactiv
respons
tar
element
polyfunct
rna
domain
mainli
involv
activ
transcript
bind
viral
protein
tat
aptam
bind
tar
element
vitro
looploop
interact
intracellular
express
aptam
nucleolar
rna
promot
inhibit
infect
strategi
take
advantag
rna
nucleolartraffick
effici
coloc
aptam
target
aptam
improv
inclus
extra
bind
rna
domain
target
addit
site
result
show
presynthes
aptam
aptam
produc
intracellularli
via
rna
promoterdriven
express
multipl
bind
site
target
whole
effici
inhibit
replic
cell
cultur
et
al
unpublish
differ
attempt
isol
rna
aptam
differ
domain
hcv
intern
ribosom
entri
site
ire
locat
within
aptam
bind
domain
iiiiv
hcv
ire
inhibit
activ
cellfre
system
inhibit
improv
conjug
chimer
molecul
target
domain
ii
rna
aptam
isol
hcv
strand
ire
domain
partial
inhibit
hcv
rna
replicasemedi
strand
synthesi
probabl
interf
strand
bind
step
forward
design
innov
select
approach
identifi
chimer
ribozymeaptam
rna
molecul
entir
hcvire
select
cycl
includ
two
consecut
select
step
bind
cleavag
viral
rna
six
select
round
seven
famili
inhibitor
rna
identifi
simultan
target
two
site
within
hcvire
one
inhibitori
domain
chimer
rna
inhibitor
promot
ire
inhibit
cell
extract
identifi
new
target
develop
antihcv
agent
character
reveal
inhibit
viral
translat
replic
human
liver
cell
line
abil
selex
gener
aptam
kind
target
provid
possibl
use
therapeut
antidot
palli
ricin
toxic
heterodimer
lectin
castor
bean
plant
ricinu
communi
disrupt
protein
synthesi
inactiv
ribosom
aptam
isol
chain
partial
restor
protein
synthesi
level
cell
free
translat
system
cell
cultur
differ
approach
explor
cocain
anticonvuls
allevi
compound
preferenti
bind
open
isoform
nicotin
acetylcholin
receptor
nachr
found
neuromuscular
junction
autonom
ganglia
central
nervou
system
rna
aptam
develop
nachr
equal
bind
affin
open
close
sodiumpotasium
channel
isoform
partial
restor
isoform
equilibrium
allevi
drug
channel
inhibit
cell
aptam
distinguish
differ
isoform
protein
differ
member
famili
aptamersirnatoxin
conjug
develop
deliv
therapeut
agent
within
specif
target
cell
ex
vivo
select
procedur
perform
specif
cell
type
yield
aptam
effici
taken
cell
could
therefor
use
specif
deliveri
tool
aptam
tenascin
c
select
human
glioma
cell
line
effici
taken
human
tumor
cell
xenograft
glioblastoma
breast
tumor
model
aptam
target
prostatespecif
membran
antigen
psma
use
deliveri
tool
coffey
group
report
two
rna
aptam
bind
specif
recombin
psma
sinc
psma
continu
recycl
cell
surfac
aptam
appropri
vehicl
deliv
therapeut
compound
via
endosom
pathway
small
interf
rna
prosurviv
factor
overexpress
prostat
cancer
cell
eukaryot
elong
factor
deliv
aptam
aptamerdriven
uptak
sirna
lead
death
psmaposit
cell
tumor
regress
follow
intratumor
inject
mice
xenograft
model
improv
deliveri
vehicl
achiev
sever
way
tumor
regress
almost
complet
loss
cell
viabil
observ
eukaryot
elong
factor
sirna
deliv
dimer
aptam
deliveri
pharmacolog
compound
aptam
also
studi
differ
approach
doxorubicin
dox
chemotherapeut
intercal
agent
use
cancer
dox
intercal
aromat
ring
gc
pair
aptam
enhanc
cytotox
psmaexpress
cell
reduc
nonexpress
cell
result
report
use
conjug
toxin
block
protein
synthesi
side
toxic
chemotherapeut
compound
prevent
encapsul
within
nanoparticl
nanoconjug
aptam
specif
also
use
deliv
sirna
infect
cell
found
surfac
infect
cell
promot
cell
fusion
consequ
besid
neutral
infect
particl
aptam
use
sirna
deliveri
infect
cell
first
attempt
involv
chimera
aptam
sirna
target
overlap
rev
tat
region
chimera
intern
aptamerdepend
manner
inhibit
depend
interfer
machineri
aptamersirna
linkag
improv
easi
combin
sirna
aptam
better
sirna
process
cellular
machineri
improv
chimera
result
specif
inhibit
replic
infect
pbmc
cultur
cem
cell
final
aptam
also
use
coloc
rna
inhibitor
specif
target
molecul
subcellular
level
aptam
target
rna
domain
eg
viral
rna
genom
therefor
improv
transcleav
ribozym
anchor
target
chimer
molecul
compos
hammerhead
ribozym
aptam
target
hcv
ire
effici
inhibit
ire
activ
human
hepatocyt
cell
cultur
procedur
use
identifi
dna
rna
molecul
interest
larg
popul
variant
nucleic
acid
molecul
contribut
significantli
develop
nucleic
acidbas
therapeut
drug
aptam
show
high
specif
target
low
toxic
immunogen
profil
sinc
design
isol
specif
aptam
use
select
evolut
techniqu
optim
even
autom
lead
great
advanc
knowledg
aptam
therapeut
agent
expand
bank
inhibitori
nucleic
acid
possibl
target
includ
cytokin
cell
receptor
virus
even
whole
cell
aptam
drug
market
sever
mid
late
clinic
trial
progress
appear
confirm
great
potenti
tool
improv
optim
select
strategi
ongo
discoveri
made
field
success
develop
nucleic
acidbas
therapeut
protocol
might
predict
